PT - JOURNAL ARTICLE AU - ANGIOLO GADDUCCI AU - STEFANIA COSIO TI - Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review AID - 10.21873/anticanres.15281 DP - 2021 Oct 01 TA - Anticancer Research PG - 4673--4685 VI - 41 IP - 10 4099 - http://ar.iiarjournals.org/content/41/10/4673.short 4100 - http://ar.iiarjournals.org/content/41/10/4673.full SO - Anticancer Res2021 Oct 01; 41 AB - Platinum/paclitaxel-based chemotherapy is able to obtain a clinical response in up to 80% of patients with advanced ovarian carcinoma, but most of them will subsequently develop recurrent disease. Several therapeutic approaches, including prolonged administration of the first-line regimen and the concomitant or sequential addition of a third cytotoxic agent to standard chemotherapy, failed to improve the clinical outcome of patients. In the last years, the implementation of the biological knowledge on ovarian carcinoma and the introduction of bevacizumab (BEV) and poly(ADP-ribose) polymerase inhibitors (PARPi) in first-line treatment have improved patient prognosis. In this review, we have analyzed the randomized clinical trials and real world observational studies on these issues, with the aim to suggest an algorithm for a rational use of BEV and PARPi in patients with newly diagnosed advanced ovarian carcinoma.